PDC-E2 Antibody (B-2): sc-271534

PDC-E2 Antibody (B-2) is a mouse monoclonal IgG2a kappa light chain antibody that detects PDC-E2 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). PDC-E2 (B-2) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. PDC-E2 plays a crucial role in the pyruvate dehydrogenase multienzyme complex, which is essential for converting pyruvate into acetyl-CoA, a key metabolic intermediate that fuels the citric acid cycle. This function is vital for energy production and metabolic regulation in cells, particularly in tissues with high energy demands such as the heart and brain. The presence of autoantibodies against PDC-E2 is a hallmark of primary biliary cirrhosis, a chronic autoimmune liver disease characterized by the destruction of bile ducts, leading to cholestasis and liver damage. PDC-E2 features a unique structure with both an amino-terminal lipoyl-bearing domain and a carboxy-terminal catalytic domain, which are critical for enzymatic activity and interaction with other proteins in the metabolic pathway. The immunodominant autoepitopes of the autoantigens correspond to the inner lipoyl domain, highlighting PDC-E2′s importance in both normal physiology and autoimmune pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PDC-E2 Antibody (B-2) References:

1. T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC).  |  Palmer, JM., et al. 1999. Clin Exp Immunol. 116: 133-9. PMID: 10209517
2. The immunopathogenesis of primary biliary cirrhosis.  |  Quaranta, S., et al. 1999. Hepatogastroenterology. 46: 3041-7. PMID: 10626157
3. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples.  |  Kisand, KE., et al. 2001. J Gastroenterol. 36: 248-54. PMID: 11324728
4. Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2.  |  Leung, PS., et al. 1990. Hepatology. 12: 1321-8. PMID: 1701753
5. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase.  |  Coppel, RL., et al. 1988. Proc Natl Acad Sci U S A. 85: 7317-21. PMID: 3174635
6. Nucleotide sequence of a cDNA for the dihydrolipoamide acetyltransferase component of human pyruvate dehydrogenase complex.  |  Thekkumkara, TJ., et al. 1988. FEBS Lett. 240: 45-8. PMID: 3191998
7. Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis.  |  Yasoshima, M., et al. 1995. J Pathol. 175: 319-25. PMID: 7538164
8. Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis.  |  Klein, R., et al. 1993. Clin Exp Immunol. 92: 308-16. PMID: 7683589
9. Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjögren's syndrome.  |  Tsuneyama, K., et al. 1994. Hepatology. 20: 893-8. PMID: 7927231
10. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary epithelium from patients with primary biliary cirrhosis.  |  Joplin, RE., et al. 1994. Hepatology. 19: 1375-80. PMID: 8188168
11. Antibody to two forms of dihydrolipoamide acetyltransferase (PDC-E2) in primary biliary cirrhosis.  |  Chen, QY., et al. 1993. Liver. 13: 130-5. PMID: 8336525
12. Three-dimensional structure of the major autoantigen in primary biliary cirrhosis.  |  Howard, MJ., et al. 1998. Gastroenterology. 115: 139-46. PMID: 9649469

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PDC-E2 Antibody (B-2) has 10 citations in a variety of scientific publications.

Primary antibodies like Anti-PDC-E2 Antibody (B-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PDC-E2 Antibody (B-2) Specifications

Alternate Product Name: PDC-E2

Product Clone Name: B-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 231-390

Epitope Target: PDC-E2

Epitope Species: human

Product Reactivity/Detection: PDC-E2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 10 citations in various scientific publications

Available Conjugates/Forms for PDC-E2 Antibody (B-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin